-
Beijing Sun-Novo Secures Exclusive Rights to Kaneka’s Skin Patch Drugs in Licensing Deal
•
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a licensing agreement with Japanese firm Kaneka Corporation, securing exclusive patent rights and technical know-how for two skin patch drugs, SN001 and SN002. The agreement covers the Chinese mainland, Hong Kong, and Macao markets, expanding the reach of these…
-
International Vaccine Institute and Nankai University Establish Joint Research Center for Vaccine Advancements
•
The International Vaccine Institute (IVI), a non-profit international organization initiated by the United Nations Development Programme (UNDP), has entered into a partnership with China’s Nankai University to establish the “International Vaccine Research Institute Nankai Joint Research Center”. This collaboration aims to enhance global health initiatives through joint efforts in vaccine…
-
MicroPort MedBot Receives NMPA Approval for Mona Lisa Prostate Puncture Robot System
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for the ISR’obot Mona Lisa prostate puncture robot positioning system. This product is a result of a joint venture between MicroPort MedBot and Biobot Surgical Pte. Ltd,…
-
Liaoning-Led Alliance Launches Volume-Based Procurement Tender for Hernia and Dural Patches
•
A 12-strong provincial procurement alliance, spearheaded by Liaoning province, has announced the initiation of a volume-based procurement (VBP) tender round focused on hernia patches, including inguinal and abdominal wall hernia patches, as well as dural (spinal) membrane patches. The alliance includes participants such as Shanxi, Inner Mongolia Autonomous Region, Jilin,…
-
Asieris Pharmaceuticals Secures Exclusive Global Rights to UroViu’s Fluorescent Imaging Cystoscope
•
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced a strategic collaboration with US firm UroViu Corporation, obtaining exclusive global rights to UroViu’s patented portable single-use cystoscope in the field of fluorescent imaging. Combining Technology for Non-Muscle Invasive Bladder Cancer (NMIBC) ResearchUnder the agreement, Asieris will utilize this patented…
-
Abbisko Therapeutics and X4 Pharmaceuticals Announce Positive Phase III Results for Mavorixafor in WHIM Syndrome
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) and its US partner X4 Pharmaceuticals Inc. have announced positive top-line data from a pivotal Phase III clinical study for the once-daily, oral CXCR4 antagonist mavorixafor. The trial is assessing the molecule as a treatment for WHIM syndrome (warts, hypogammaglobulinemia, infections, and…
-
Shenzhen Kangtai Biological Partners with Saudi Importer for Pneumonia Vaccine Distribution
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with a drug importer in Saudi Arabia to promote the regulatory filing, marketing, and sales of its 13-valent and 23-valent pneumonia vaccines in the country. The local partner will handle the regulatory filing and approval process…
-
FibroGen’s Roxadustat Shows Positive Results in Phase III Chemotherapy-Induced Anemia Trial
•
US-based FibroGen Inc. (NASDAQ: FGEN) has announced positive topline data from a Phase III trial for roxadustat, a treatment for anemia in patients receiving chemotherapy. The study, which focused on 153 patients in China (NCT05301517), showed that detailed results will be presented at a future industry conference. Roxadustat’s Efficacy and…
